Search Results

There are 11207 results for: content related to: Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

  1. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Version of Record online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  2. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  3. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Version of Record online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  4. You have free access to this content
    2011 International Melanoma Congress

    Pigment Cell & Melanoma Research

    Volume 24, Issue 5, October 2011, Pages: 990–1075,

    Version of Record online : 10 OCT 2011, DOI: 10.1111/j.1755-148X.2011.00909.x

  5. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  6. You have free access to this content
    Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma

    IUBMB Life

    Volume 65, Issue 9, September 2013, Pages: 748–758, Ao-Xue Wang and Xiao-Yi Qi

    Version of Record online : 29 JUL 2013, DOI: 10.1002/iub.1193

  7. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  8. You have full text access to this OnlineOpen article
    Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

    Pigment Cell & Melanoma Research

    Volume 27, Issue 2, March 2014, Pages: 253–262, Jaehyuk Choi, Sean F. Landrette, Tiffany Wang, Perry Evans, Antonella Bacchiocchi, Robert Bjornson, Elaine Cheng, Amy L. Stiegler, Symon Gathiaka, Orlando Acevedo, Titus J. Boggon, Michael Krauthammer, Ruth Halaban and Tian Xu

    Version of Record online : 6 JAN 2014, DOI: 10.1111/pcmr.12197

  9. PTEN regulates IGF-1R-mediated therapy resistance in melanoma

    Pigment Cell & Melanoma Research

    Volume 28, Issue 5, September 2015, Pages: 572–589, Jun Wang, Tobias Sinnberg, Heike Niessner, Rebecca Dölker, Birgit Sauer, Wolfgang E. Kempf, Friedegund Meier, Nick Leslie and Birgit Schittek

    Version of Record online : 16 AUG 2015, DOI: 10.1111/pcmr.12390

  10. You have full text access to this OnlineOpen article
    Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

    EMBO Molecular Medicine

    Volume 7, Issue 9, September 2015, Pages: 1104–1118, Kristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, Aida Shahrabi, Fleur Weeber, Ji-Ying Song, Thomas Kuilman, Daniel J Vis, Lodewyk F Wessels, Emile E Voest, Ton NM Schumacher, Christian U Blank, David J Adams, John B Haanen and Daniel S Peeper

    Version of Record online : 23 JUN 2015, DOI: 10.15252/emmm.201404914

  11. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  12. The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells

    International Journal of Cancer

    Luca Hegedũs, Tamás Garay, Eszter Molnár, Karolina Varga, Ágnes Bilecz, Szilvia Török, Rita Padányi, Katalin Pászty, Matthias Wolf, Michael Grusch, Enikõ Kállay, Balázs Döme, Walter Berger, Balázs Hegedũs and Agnes Enyedi

    Version of Record online : 17 NOV 2016, DOI: 10.1002/ijc.30503

  13. Abstracts from the 32nd Annual Meeting of the Histiocyte Society Dublin, Ireland October 17–19, 2016

    Pediatric Blood & Cancer

    Volume 63, Issue S2, November 2016, Pages: S10–S65,

    Version of Record online : 31 AUG 2016, DOI: 10.1002/pbc.26239

  14. Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 24–31, S Jang and MB Atkins

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.197

  15. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation

    Molecular Carcinogenesis

    Volume 56, Issue 1, January 2017, Pages: 49–61, Aishwarya Kundu, Jeanne G. Quirit, Michelle G. Khouri and Gary L. Firestone

    Version of Record online : 15 FEB 2016, DOI: 10.1002/mc.22472

  16. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

    British Journal of Dermatology

    Volume 168, Issue 4, April 2013, Pages: 700–707, D. Gonzalez, L. Fearfield, P. Nathan, P. Tanière, A. Wallace, E. Brown, C. Harwood, J. Marsden and S. Whittaker

    Version of Record online : 25 MAR 2013, DOI: 10.1111/bjd.12248

  17. Developing melanoma therapeutics: overview and update

    Wiley Interdisciplinary Reviews: Systems Biology and Medicine

    Volume 5, Issue 3, May/June 2013, Pages: 257–271, John B. Korman and David E. Fisher

    Version of Record online : 13 FEB 2013, DOI: 10.1002/wsbm.1210

  18. You have free access to this content
    Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

    Cancer

    Volume 121, Issue 3, February 1, 2015, Pages: 448–456, Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn and Mark G. Kris

    Version of Record online : 1 OCT 2014, DOI: 10.1002/cncr.29042

  19. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

    Pigment Cell & Melanoma Research

    Volume 26, Issue 4, July 2013, Pages: 509–517, Kaitlyn Le, Erik S. Blomain, Ulrich Rodeck and Andrew E. Aplin

    Version of Record online : 8 APR 2013, DOI: 10.1111/pcmr.12092

  20. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 327–339, Inna V. Fedorenko, Bin Fang, Ana Cecelia Munko, Geoffrey T. Gibney, John M. Koomen and Keiran S. M. Smalley

    Version of Record online : 17 DEC 2014, DOI: 10.1002/pmic.201400200